1-2 of 2
Dan Pollyea
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes following lower-intensity therapy with venetoclax in patients with NPM1-mutated Acute Myeloid Leukemia are highly dependent upon co-occurring mutations

Free
Curtis Lachowiez, Seongseok Yun, Mael Heiblig, Michael Heuser, Rabia Shahswar, Anand Patel, Rafael Madero-Marroquin, Joseph Cannova, Dimitrios Drekolias, Fatima Tuz Zahra, Amine Belhabri, Urbain Tauveron-Jalenques, Emmanuelle Tavernier, Martin Carre, Gaspar Aspas Requena, Jenny O'Nions, Faisal Basheer, John Laurie, Ellen Madarang, Richard Dillon, Sanam Loghavi, Joshua Zeidner, Dan Pollyea, Justin Watts, Jad Othman
Journal: Blood
Blood (2025) 146 (Supplement 1): 5278.
https://doi.org/10.1182/blood-2025-5278
Published: 2025
Journal Articles

Updated response and safety analyses from a Phase 1 study of ivosidenib combined with intensive chemotherapy in patients with newly diagnosed (ND) Acute Myeloid Leukemia with isocitrate dehydrogenase (IDH)1 mutation

Free
Eytan Stein, Courtney DiNardo, Amir Fathi, Alice Mims, Keith Pratz, Michael Savona, Anthony Selwyn Stein, Richard Stone, Eric Winer, Christopher Seet, Hartmut Döhner, Dan Pollyea, James McCloskey, Olatoyosi Odenike, Bob Lowenberg, Gert J. Ossenkoppele, Mikhail Roshal, Sung Choe, Qian Meng, Stephanie Kapsalis, Prapti Patel, Hagop Kantarjian, Martin Tallman
Journal: Blood
Blood (2025) 146 (Supplement 1): 992.
https://doi.org/10.1182/blood-2025-992
Published: 2025